Utilization Patterns of Coagulation Factor Consumption for Patients with Hemophilia.
10.3346/jkms.2016.31.1.33
- Author:
Soo Ok LEE
1
;
Su Yeon YU
Author Information
1. Health Insurance Review and Assessment Services, Seoul, Korea. suyeony@hiramail.net
- Publication Type:Original Article
- Keywords:
Hemophilia;
Coagulation Factor;
Utilization;
Cost
- MeSH:
Adolescent;
Adult;
Aged;
Blood Coagulation Disorders, Inherited/*drug therapy/*economics/pathology;
Blood Coagulation Factors/*therapeutic use;
Child;
Child, Preschool;
Databases, Factual;
Female;
Humans;
Infant;
Infant, Newborn;
Male;
Middle Aged;
National Health Programs/statistics & numerical data;
Republic of Korea;
Severity of Illness Index;
Young Adult
- From:Journal of Korean Medical Science
2016;31(1):33-38
- CountryRepublic of Korea
- Language:English
-
Abstract:
Hemophilia is a serious rare disease that requires continuous management and treatment for which the medicine is costly at the annual average of 100 million KRW for an individual. The aim of this study was to investigate trends in the utilization of coagulation factor (CF) used for hemophilia treatment using the National Health Insurance database from 2010 to 2013 in Korea and compare the utilization of CF with other countries. The consumption of CF per capita (IU) in Korea was not more than other countries with similar income to Korea. However, CF usage per patient IU was higher because the prevalence rate of hemophilia in Korea was lower than in other countries while the number of serious patients was much more. Therefore, it is difficult to say that the consumption of hemophilia medicine in Korea is higher than that in other countries. The consumption and cost of hemophilia medicine in Korea is likely to increase due to the increased utilization of expensive bypassing agents and the widespread use of prophylaxis for severe hemophilia. Even during the research period, it increased slightly and other countries show a similar trend. Thus, hemophilia patient management should accompany active monitoring on the health and cost outcomes of pharmaceutical treatment in the future. This study is expected to contribute to further insight into drug policies for other countries that face similar challenges with high price pharmaceuticals.
